Reloxaliase

Summary

Reloxaliase (CHEMBL4297818) is a phase-3 clinical-stage enzyme; indicated across 1 condition including primary hyperoxaluria.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Enzyme
• Indications: 1 condition
• Clinical trials: 5

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL4297818
Name	Reloxaliase
Type	Enzyme
Max phase	3

Also known as: Alln-177, Reloxaliasa, Reloxaliase, RELOXALIASE

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

1 disease in clinical trials (phase 1–3, investigational — not approved indications). Highest ChEMBL trial phase per disease; a non-cancer approved use is occasionally logged at phase 3 here.

Disease (in trials)	Phase	MONDO	EFO
primary hyperoxaluria	3	MONDO:0002474	MONDO:0002474

Clinical trials

Total trials: 5.

Phase distribution

Phase	Trials
PHASE2	3
PHASE3	2

Top trials by phase / activity

NCT	Phase	Status	Title
NCT03456830	PHASE3	COMPLETED	Evaluate ALLN-177 in Patients With Enteric Hyperoxaluria
NCT03847090	PHASE3	TERMINATED	Establishing the Safety and Efficacy of Reloxaliase in Patients With Enteric Hyperoxaluria
NCT02289755	PHASE2	COMPLETED	Evaluating ALLN-177 for Reducing Urinary Oxalate Excretion in Calcium Oxalate Kidney Stone Formers With Hyperoxaluria
NCT02547805	PHASE2	COMPLETED	Evaluate the Effect of ALLN-177 in Reducing Urinary Oxalate in Patients With Secondary Hyperoxaluria and Kidney Stones Over 28 Days
NCT03391804	PHASE2	COMPLETED	Study of ALLN-177 in Patients Aged 12 Years or Older With Enteric or Primary Hyperoxaluria and Hyperoxalemia

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).